Teladoc Inc (TDOC) is Granahan Investment Management Inc. MA’s 6th Largest Position

Granahan Investment Management Inc. MA decreased its position in Teladoc Inc (NYSE:TDOC) by 27.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 572,229 shares of the health services provider’s stock after selling 220,342 shares during the period. Teladoc accounts for 2.0% of Granahan Investment Management Inc. MA’s investment portfolio, making the stock its 6th biggest holding. Granahan Investment Management Inc. MA owned 0.82% of Teladoc worth $33,218,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of TDOC. Trustees of Princeton University bought a new position in Teladoc in the 2nd quarter worth approximately $2,502,000. MetLife Investment Advisors LLC boosted its holdings in Teladoc by 12.0% in the 2nd quarter. MetLife Investment Advisors LLC now owns 28,383 shares of the health services provider’s stock worth $1,648,000 after buying an additional 3,032 shares during the period. Metropolitan Life Insurance Co. NY boosted its holdings in Teladoc by 12.5% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 20,045 shares of the health services provider’s stock worth $1,164,000 after buying an additional 2,228 shares during the period. Bank of America Corp DE boosted its holdings in Teladoc by 82.8% in the 2nd quarter. Bank of America Corp DE now owns 1,883,185 shares of the health services provider’s stock worth $109,318,000 after buying an additional 853,076 shares during the period. Finally, Zevenbergen Capital Investments LLC boosted its holdings in Teladoc by 3.9% in the 2nd quarter. Zevenbergen Capital Investments LLC now owns 1,629,170 shares of the health services provider’s stock worth $94,574,000 after buying an additional 61,325 shares during the period.

Shares of NYSE:TDOC opened at $77.30 on Friday. The company has a current ratio of 3.14, a quick ratio of 3.14 and a debt-to-equity ratio of 0.58. Teladoc Inc has a one year low of $27.30 and a one year high of $79.64.

Teladoc (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, August 1st. The health services provider reported ($0.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.01. Teladoc had a negative net margin of 37.78% and a negative return on equity of 19.10%. The firm had revenue of $94.60 million during the quarter, compared to the consensus estimate of $91.56 million. During the same period last year, the firm earned ($0.28) EPS. The business’s quarterly revenue was up 112.1% compared to the same quarter last year. equities research analysts predict that Teladoc Inc will post -1.51 EPS for the current fiscal year.

TDOC has been the subject of several analyst reports. Piper Jaffray Companies raised their price objective on shares of Teladoc to $46.00 and gave the stock an “overweight” rating in a report on Monday, June 4th. Craig Hallum raised shares of Teladoc from a “hold” rating to a “buy” rating in a report on Tuesday, June 5th. JPMorgan Chase & Co. raised their price objective on shares of Teladoc to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, June 5th. Canaccord Genuity raised their price objective on shares of Teladoc from $47.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, June 5th. Finally, SunTrust Banks raised their price objective on shares of Teladoc from $48.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, June 5th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $65.10.

In other Teladoc news, SVP Andrew Turitz sold 13,821 shares of the firm’s stock in a transaction on Tuesday, July 3rd. The shares were sold at an average price of $59.43, for a total value of $821,382.03. Following the completion of the transaction, the senior vice president now directly owns 9,378 shares of the company’s stock, valued at approximately $557,334.54. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Mark Hirschhorn sold 20,000 shares of the firm’s stock in a transaction on Tuesday, July 10th. The shares were sold at an average price of $63.00, for a total transaction of $1,260,000.00. Following the completion of the transaction, the vice president now directly owns 2,791 shares of the company’s stock, valued at $175,833. The disclosure for this sale can be found here. Over the last three months, insiders sold 242,497 shares of company stock valued at $16,108,269. Insiders own 3.95% of the company’s stock.

Teladoc Company Profile

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Story: Exchange-Traded Funds (ETFs)

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Inc (NYSE:TDOC).

Institutional Ownership by Quarter for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply